Frederike Bensch

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial IRF progression-free survival and overall survival were longer in the lurbinectedin plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit with a higher incidence of adv...

ICYMI—Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

🔗 tinyurl.com/4fmmez9w #ASCO25

Brief Report: Real-World Clinical Utility of Next-Generation Sequencing of Circulating Tumor DNA for Patients with Advanced Lung Squamous Cell Carcinoma (SQUIN) Next-generation sequencing (NGS) of tissue or plasma circulating tumor DNA (ctDNA) can detect a wide spectrum of genomic alterations (GAs), guiding treatment decisions in patients with non-small cell ...

This study found ALK, EGFR, BRAF & MET in 4% of squamous lung cancer cases. NGS matters—because finding the right mutation means access to the right treatment.

🔗 www.clinical-lung-cancer.com/article/S152...

#LCSM

Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03 - PubMed SG demonstrated promising efficacy in the second-line treatment of ES-SCLC, irrespective of platinum sensitivity. Safety was manageable and consistent with that observed in other SG studies.

Ongoing search for effective 2nd line treatment in 🫁 cancer.

Sacituzumab Govitecan (TROP2 ADC) in ED SCLC in ph. 2 TROPiCS-03. ORR 41.9% (35% in platinum-res). PFS 4.4 mo, OS 13.6 mo. 74.4% >=gr.3 tox.

Despite advancements, need to do better (selection?).

pubmed.ncbi.nlm.nih.gov/39755168/

Preparing local guidelines for 2025.

TNM9 for the classification of lung cancer.

journal.chestnet.org/article/S001...